Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05709912 · ClinicalTrials.gov registry record · NA

Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant

A NA study of Hematologic Malignancy and Bone Marrow Transplant Complications, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05709912 is a NA study of Hematologic Malignancy and Bone Marrow Transplant Complications that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 120 participants, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05709912, a NA study of Hematologic Malignancy and Bone Marrow Transplant Complications, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT).

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL CARE Application

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-07-01
Est. Completion 2026-12-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05709912

The ClinicalTrials.gov registry entry for NCT05709912 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (47% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT05709912 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05709912 about?

NCT05709912 is a clinical study titled "Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant". The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (HCT).

What is the current status of trial NCT05709912?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-07-01. Estimated completion is 2026-12-01.

What conditions does trial NCT05709912 study?

This clinical trial studies the following conditions: Hematologic Malignancy, Bone Marrow Transplant Complications.

What interventions are being tested in trial NCT05709912?

The interventions under investigation include: Usual Care (BEHAVIORAL), CARE Application (BEHAVIORAL).

Who is sponsoring clinical trial NCT05709912?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05709912 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematologic Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.